ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX:ANPCY) announced a change in its advisory team, appointing Berenberg as its Nominated Adviser and Joint Broker, and Jefferies as its Joint Broker, effective immediately. This strategic move aims to strengthen the company's market position as a leading liquid biopsy enterprise. ANGLE's proprietary Parsortix system, which targets circulating tumor cells for cancer analysis, is progressing towards FDA clearance for use with metastatic breast cancer patients and has shown promising results in clinical studies for ovarian cancer diagnostics.

ANGLE plc has announced the issuance of 15,666 new ordinary shares following employee option exercises. The New Ordinary Shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 27, 2021. This brings the total number of ordinary shares to 234,942,051, enhancing total voting rights.

ANGLE specializes in liquid biopsy technologies, particularly the Parsortix system, which captures circulating tumor cells for cancer analysis. The company continues to progress its clinical studies and patent portfolio.

ANGLE plc (OTCQX: ANPCY) announced the issuance of 30,000 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 21, 2021. After this issuance, the total number of ordinary shares in circulation will be 234,926,385, impacting the total voting rights accordingly. ANGLE is recognized for its liquid biopsy technology, particularly the Parsortix system, which captures cancer cells for further analysis.

ANGLE plc (OTCQX: ANPCY), a leader in liquid biopsy technology, announced the issuance of 48,334 new ordinary shares following employee option exercises. These shares will rank equally with existing shares, bringing the total to 234,896,385 shares post-admission. The shares are expected to be traded on AIM starting October 6, 2021. This move does not directly reflect on revenue or market performance but indicates continued employee engagement and corporate governance.

ANGLE plc (OTCQX: ANPCY) reported its interim results for the six months ended June 30, 2021. Revenue rose to £0.3 million from £0.2 million in H1 2020, while losses increased to £7.7 million from £3.4 million. The company is progressing with its FDA submission for the Parsortix system, expecting a response in H2 2021. A new global pharma services business has been launched, with contracts in progress. The ovarian cancer clinical study is nearing completion, with results anticipated in Q4 2021.

ANGLE plc has announced significant findings from studies presented at the 5th Advances in Circulating Tumour Cells (ACTC) conference. The research utilizing ANGLE's Parsortix system identified novel circulating tumor cell (CTC) biomarkers in ovarian and lung cancer, indicating potential for personalized treatment. A Phase II trial showed that gene analysis of CTCs could predict patient responses, with 85% survival for responders at 120 days. Additional studies highlighted the presence of p53 protein in small cell lung cancer and identified crucial markers for non-small cell lung cancer prognosis.

ANGLE plc has announced that a study from the Health Research Institute of Santiago demonstrates the effectiveness of the Parsortix system in assessing PD-L1 status in circulating tumor cells (CTCs) for non-small cell lung cancer (NSCLC) patients. This liquid biopsy method, which is safer than traditional tissue biopsies, offers a promising approach to monitor treatment responses. ANGLE is further developing a PD-L1 assay for use in cancer drug trials and aims to collaborate with leading cancer centers for validation. The study highlights the need for improved patient selection due to low response rates to current therapies.

ANGLE plc has announced significant advancements with its Parsortix system in analyzing gene expression in metastatic prostate cancer (mPCa) patients. A study by the Medical University of Innsbruck revealed that Parsortix successfully isolated circulating tumor cells (CTCs) in 80% of patients, offering a viable alternative when tissue biopsies are not possible. Longitudinal monitoring indicated a drop in CTCs correlating with positive drug responses, further underscoring its potential for pharma services. With approximately 3.2 million U.S. men living with prostate cancer, these findings may guide personalized treatment decisions.

ANGLE plc (OTCQX:ANPCY) will release its interim results for the six months ending June 30, 2021, on September 30, 2021. A virtual meeting for analysts starts at 10:00 AM BST the same day. Registration is required to attend the webcast, which serves as a watch-only platform with Q&A reserved for analysts. ANGLE is a leader in liquid biopsy, known for its Parsortix technology enabling non-invasive cancer cell analysis. The company aims for FDA clearance for CTC harvesting, which could elevate its market position significantly.